Management of Malignant Ureteric Obstruction with Ureteric Stenting or Percutaneous Nephrostomy

Overview

Journal Br J Surg

Specialty General Surgery

Date 2024 Feb 26

PMID 38406883

Authors

James Blackmur

Affiliations

Soon will be listed here.

References

Izumi K, Mizokami A, Maeda Y, Koh E, Namiki M . Current outcome of patients with ureteral stents for the management of malignant ureteral obstruction. J Urol. 2010; 185(2):556-61. DOI: 10.1016/j.juro.2010.09.102. View

Alawneh A, Tuqan W, Innabi A, Al-Nimer Y, Azzouqah O, Rimawi D . Clinical Factors Associated With a Short Survival Time After Percutaneous Nephrostomy for Ureteric Obstruction in Cancer Patients: An Updated Model. J Pain Symptom Manage. 2015; 51(2):255-61. DOI: 10.1016/j.jpainsymman.2015.09.009. View

Ishioka J, Kageyama Y, Inoue M, Higashi Y, Kihara K . Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol. 2008; 180(2):618-21. DOI: 10.1016/j.juro.2008.04.011. View

Wilson J, Urwin G, Stower M . The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl. 2005; 87(1):21-4. PMC: 1963830. DOI: 10.1308/1478708051432. View

Khafagy R, Shackley D, Samuel J, OFlynn K, Betts C, Clarke N . Complications arising in the final year of life in men dying from advanced prostate cancer. J Palliat Med. 2007; 10(3):705-11. DOI: 10.1089/jpm.2006.0185. View

Shekarriz B, Shekarriz H, Upadhyay J, Banerjee M, Becker H, Pontes J . Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer. 1999; 85(4):998-1003. DOI: 10.1002/(sici)1097-0142(19990215)85:4<998::aid-cncr30>3.0.co;2-f. View

Yu S, Ryu J, Jeong S, Hwang E, Jang W, Hwang I . Predicting factors for stent failure-free survival in patients with a malignant ureteral obstruction managed with ureteral stents. Korean J Urol. 2013; 54(5):316-21. PMC: 3659225. DOI: 10.4111/kju.2013.54.5.316. View

Romero F, Broglio M, Pires S, Roca R, Guibu I, Perez M . Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias. Int Braz J Urol. 2005; 31(2):117-24. DOI: 10.1590/s1677-55382005000200005. View

Andrassy K . Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int. 2013; 84(3):622-3. DOI: 10.1038/ki.2013.243. View

10.

Nathan A, Morris M, Parry M, Berry B, Sujenthiran A, Nossiter J . Interventions for obstructive uropathy in advanced prostate cancer: a population-based study. BJU Int. 2022; 130(5):688-695. DOI: 10.1111/bju.15766. View

11.

Forrest L, McMillan D, McArdle C, Angerson W, Dunlop D . Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004; 90(9):1704-6. PMC: 2409737. DOI: 10.1038/sj.bjc.6601789. View

12.

Aravantinos E, Anagnostou T, Karatzas A, Papakonstantinou W, Samarinas M, Melekos M . Percutaneous nephrostomy in patients with tumors of advanced stage: treatment dilemmas and impact on clinical course and quality of life. J Endourol. 2007; 21(11):1297-302. DOI: 10.1089/end.2006.0104. View

13.

Folkard S, Banerjee S, Menzies-Wilson R, Reason J, Psallidas E, Clissold E . Percutaneous nephrostomy in obstructing pelvic malignancy does not facilitate further oncological treatment. Int Urol Nephrol. 2020; 52(9):1625-1628. DOI: 10.1007/s11255-020-02466-2. View

14.

Izumi K, Shima T, Shigehara K, Sawada K, Naito R, Kato Y . A novel risk classification score for malignant ureteral obstruction: a multicenter prospective validation study. Sci Rep. 2021; 11(1):4455. PMC: 7904864. DOI: 10.1038/s41598-021-84054-7. View

15.

Cordeiro M, Coelho R, Chade D, Pessoa R, Chaib M, Colombo-Junior J . A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients. BJU Int. 2014; 117(2):266-71. DOI: 10.1111/bju.12963. View

16.

Ni X, Wu J, Ji M, Shao Y, Xu B, Jiang J . Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac J Clin Oncol. 2018; 14(6):402-409. DOI: 10.1111/ajco.13055. View

17.

Fan Z, Fan K, Gong Y, Huang Q, Yang C, Cheng H . The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. Cancer Manag Res. 2019; 11:8781-8788. PMC: 6778322. DOI: 10.2147/CMAR.S211363. View

18.

Zhang K, Zhang Y, Chao M . Which is the best way for patients with ureteral obstruction? Percutaneous nephrostomy versus double J stenting. Medicine (Baltimore). 2022; 101(45):e31194. PMC: 9666138. DOI: 10.1097/MD.0000000000031194. View

19.

Gasparini M, Carroll P, Stoller M . Palliative percutaneous and endoscopic urinary diversion for malignant ureteral obstruction. Urology. 1991; 38(5):408-12. DOI: 10.1016/0090-4295(91)80227-x. View

20.

Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K . The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014; 22(3):803-10. DOI: 10.1245/s10434-014-4048-0. View